(Q45939744)

18 December 2017

title

NSAIDs and aspirin: notorious or FAMOUS? (English)

1 reference

18 December 2017

1 reference

C J Hawkey

1

1 reference

18 December 2017

language of work or name

English

0 references

publication date

3 July 2009

1 reference

18 December 2017

published in

The Lancet

1 reference

18 December 2017

volume

374

1 reference

18 December 2017

issue

9684

1 reference

18 December 2017

page(s)

93-94

1 reference

18 December 2017

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Safer NSAID strategies: consensus or contentious?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961245-9

7 January 2021

10.1016/S0140-6736(09)61245-9

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017